Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies

B Fraile, J Alcover, M Royuela, D Rodríguez… - Future …, 2017 - Taylor & Francis
B Fraile, J Alcover, M Royuela, D Rodríguez, C Chaves, R Palacios, N Piqué
Future Microbiology, 2017Taylor & Francis
Aim: To assess the properties of a medical device containing xyloglucan, propolis and
hibiscus to create a bioprotective barrier to avoid the contact of uropathogenic Escherichia
coli strains on cell walls in models of intestinal (CacoGoblet) and uroepithelial (RWPE-1)
cells (derived from normal human prostate epithelium). Materials & methods: Two
uropathogenic E. coli strains (expressing type 1 fimbriae and P fimbriae) were used to
assess, by electronic microscopy and ELISA, the barrier properties of the medical device …
Aim
To assess the properties of a medical device containing xyloglucan, propolis and hibiscus to create a bioprotective barrier to avoid the contact of uropathogenic Escherichia coli strains on cell walls in models of intestinal (CacoGoblet) and uroepithelial (RWPE-1) cells (derived from normal human prostate epithelium).
Materials & methods
Two uropathogenic E. coli strains (expressing type 1 fimbriae and P fimbriae) were used to assess, by electronic microscopy and ELISA, the barrier properties of the medical device. The antimicrobial activity was assessed in broth dilution assays.
Results
The three components (xyloglucan, propolis and hibiscus) did not alter E. coli cell integrity in intestinal and uroepithelial cell models and were devoid of antibacterial activity. The three components avoided bacterial contact in both cell monolayers.
Conclusion
The nonpharmacological barrier properties of xyloglucan, propolis and hibiscus confirm the role of the medical device for the management of urinary tract infections.
Taylor & Francis Online